Apellis Pharmaceuticals (APLS) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a negative opinion for the second time on the marketing authorization application (MAA) for intravitreal pegcetacoplan to treat geographic atrophy (GA) in the EU. Despite this decision, there were several dissenting votes among CHMP members. Apellis plans to request a re-examination of the opinion and anticipates a final decision in the fourth quarter of 2 ...